Additionally, dietary protein-derived metabolites, including tryptophan-indole, as well as LPS from Gram-negative bacteria, directly promote the production of GLP-1 (66, 67)
While CMSs approach to Medicare obesity drug coverage after the short-term Bridge program ends is unknown, a financially sustainable solution for how to cover GLP-1 drugs for obesity remains elusive.
Ziltivekimab, a new monoclonal antibody directed against IL-6, has been specifically designed for patients with atherosclerosis and high cardiovascular risk and is being evaluated both in patients with atherosclerosis and CKD and in patients with HFpEF [20,21,22]
Andermann ML, Lowell BB
Enhanced Support and Monitoring Med spas provide a supportive environment where patients can receive continuous guidance throughout their weight loss journey
But as evidence mounts that many patients discontinue treatment and regain weight, convenience alone may not be enough to attract and retain consumers